Skip to content
value.today
Evogene Ltd. logo

Evogene Ltd.

EVGN
$8 Mmarket cap on Aug 1, 2026-80.0% since Jan 2024
Compare
World rank
#26,221
Revenue
$4 M
For year ending December-2025
Net income
$-8 M
-220.3% margin
SEC filing
Employees
—

Evogene Ltd. in brief

Evogene Ltd. is a listed company in the Biotechnology industry, based in Israel. It was founded in 2002. Its market value was $8 M on 1 August 2026, which makes it the 26,221st largest listed company in the world and the 276th largest in Israel on this site. In the year to December 2025 it had sales of $4 M and a net loss of $8 M. Ofer Haviv is its chief executive. Its largest business segments by sales in 2025 were Industrial application (56%) and Agriculture (36%). Its shares trade under the symbol EVGN (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Evogene Ltd.

If we are unable to efficiently produce and scale up the production of our products, whether ourselves or through third party contractors, we may be unable to achieve our commercialization targets.

When we introduce a product to the market, and in certain cases even in later stages of product development, we need to establish efficient production capabilities for our products. In most cases, our products are, or are expected to be, produced by third party producers with whom we contract for such purpose. The production of our products, and the scale up of such production, are complicated processes that require expertise. The production of all of our subsidiaries’ current commercial products (mainly being castor beans of Casterra) relies, in all or in part, on third-party contractors. Failure to establish a long-term relationship with a manufacturer with sufficient capacity, relevant cost of goods sold and sufficient quality, will affect our subsidiaries’ ability to meet demand for their products. If we or our third-party contractors are unable to efficiently produce and scale up production as needed to meet the demand for our products, we may be unable to achieve our commercialization targets, which may, in turn, materially and adversely affect our future results of operations.

From the company's annual report filed with the US SEC: read the report

Evogene Ltd. timeline

2 events, 2002–2013
  1. 2002
  2. 🏁
    · approximate
    Founded
  3. 2013
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.

Events of Evogene Ltd. from Wikidata and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$46 M$92 M$139 M$185 M2020202120222023202420252026

World rank over time

▼ down 654 places since 2020
2020-01-01: #22537#22,53720202021-01-01: #16118#16,11820212022-01-07: #24662#24,66220222022-12-25: #27438#27,43820222023-07-30: #25069#25,06920232024-01-05: #25929#25,92920242026-03-08: #13142#13,14220262026-08-01: #23191#23,1912026

Rank in Israel: #286 (Jan 2020) · #179 (Jan 2021) · #349 (Jan 2022) · #348 (Dec 2022) · #319 (Jul 2023) · #343 (Jan 2024) · #56 (Mar 2026) · #276 (Aug 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
2.1×
Price / book
—
Free cash flow yield
-170.5%
Net margin (TTM)
-220.3%
Operating margin
-364.4%
Return on equity
—
Liabilities / assets
40.2%
Revenue growth
-31.0%
R&D / revenue
207.5%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $2M, net income $-21M$2MFY18Fiscal year ending Dec 2019: revenue $1M, net income $-18M$1MFY19Fiscal year ending Dec 2020: revenue $1M, net income $-23M$1MFY20Fiscal year ending Dec 2021: revenue $1M, net income $-28M$1MFY21Fiscal year ending Dec 2022: revenue $2M, net income $-27M$2MFY22Fiscal year ending Dec 2023: revenue $3M, net income $-24M$3MFY23Fiscal year ending Dec 2024: revenue $6M, net income $-16M$6MFY24Fiscal year ending Dec 2025: revenue $4M, net income $-8M$4MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$4M-31.0%$-14M$-8M-220.3%
Dec 2024$6M+87.2%$-19M$-16M-295.3%
Dec 2023$3M+77.4%$-22M$-24M-801.3%
Dec 2022$2M+80.6%$-27M$-27M-1585.7%
Dec 2021$1M-10.6%$-31M$-28M-2988.2%
Dec 2020$1M+38.7%$-25M$-23M-2247.1%
Dec 2019$1M-57.1%$-21M$-18M-2414.7%
Dec 2018$2M—$-20M$-21M-1186.3%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-14M$0M$-14M$1.08—
Dec 2024$-20M$1M$-20M$-2.90—
Dec 2023$-22M$1M$-22M$-5.20—
Dec 2022$-24M$1M$-25M$-6.44—
Dec 2021$-25M$1M$-26M$-0.69—
Dec 2020$-20M$1M$-20M$-0.83—
Dec 2019$-18M$1M$-19M——
Dec 2018$-15M$0M$-16M——

SEC filings

Official filings of Evogene Ltd. with the US Securities and Exchange Commission.

Annual results

Revenue
$4 M
Operating income
$-14 M
Net income
$-8 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$20 M
Total liabilities
$8 M
Total equity
$-0 M

As of December-2025

Top 12 institutional investors in Evogene Ltd.#

As of Sep 30, 2026
12 institutions held 423,356 shares on Sep 30, 2026. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 12 largest institutional investors in Evogene Ltd.
#InstitutionShares heldChange (shares)ValueFiled
1Citadel Advisors LLC305,462+254,936 (+504.56%)$0 MNov 16, 2026
2XTX Topco Ltd101,868+82,464 (+424.98%)$0 MNov 16, 2026
3Jane Street Group, LLC10,812New$0 MNov 12, 2026
4Morgan Stanley2,685+1,400 (+108.95%)$0 MNov 13, 2026
5BNP Paribas Financial Markets1,100-1,730 (-61.13%)$0 MNov 12, 2026
6Daytona Street Capital LLC534-8,719 (-94.23%)$0 MOct 15, 2026
7Federation des caisses Desjardins du Quebec5000 (0.00%)$0 MNov 16, 2026
8UBS Group AG106-10,684 (-99.02%)$0 MNov 10, 2026
9Osaic Holdings, Inc.1000 (0.00%)$0 MNov 12, 2026
10Robinhood Markets, Inc.85—$0 MNov 18, 2026
11SBI Securities Co., Ltd.620 (0.00%)$0 MOct 22, 2026
12Royal Bank Of Canada420 (0.00%)$0 MNov 16, 2026

Mutual funds holding Evogene Ltd.#

1 funds hold shares worth $0 M. Since their previous reports 0 added shares and 0 sold.
Mutual funds holding Evogene Ltd.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC4,198$0 M—<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of May 31, 2026. The 1 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Evogene Ltd.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
695 K
3 purchases, 2 insiders
Sold, 12 months
0
0 sales, 0 insiders
Net, 12 months
695 K
open market only
Insiders on file
2
since
$694 K$0Jun 2026: bought $677 (1 trades), sold $0 (0 trades)Jun 26Aug 2026: bought $694 K (2 trades), sold $0 (0 trades)Aug
Bought (open market)Sold (open market)Hover a month for the totals
Evogene Ltd.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Leon RecanatiDirectorBuy+460,0000.640294 Klocal1.34 MForm 4
filed Leon RecanatiDirectorBuy+800,0000.500400 Klocal883,886Form 4
filed Gabi TarcicChief Development OfficerBuy+1,1290.600677local1,129Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals. This company files with the SEC as a foreign issuer; its insiders often report prices in the home currency, so amounts are as filed and not converted to dollars

Markets and events: Evogene Ltd.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
70,324
2.33 days to cover
Shares sold short, last 24 reportsAll stocks →

Fails to deliver

  • : 896 shares at $0.38
  • : 9 shares at $0.36
  • : 943 shares at $0.37
  • : 217 shares at $0.36
  • : 3,100 shares at $0.38

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Evogene Ltd. scorecard#

Passes 5 of the 11 checks that could be worked out: strongest in growth (4 of 6), weakest in profitability (1 of 4). Fiscal year 2025; market cap of Aug 1, 2026.

  • Valuationnot known
    • –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
    • –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
    • –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
  • Growth4 of 6
    • ✗Revenue grew in the newest year-31.0%Revenue down 31.0% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years31.8%31.8% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median31.8%31.8% a year against Biotechnology's median of 12.9% (181 companies).
    • ✓Earnings per share grew in the newest year1.08 vs -2.90Diluted EPS 1.08 in fiscal 2025 against -2.90 the year before (report's currency).
    • ✓Net income higher than five years earlier-$8 M-$8 M in fiscal 2025 against -$23 M in 2020.
    • ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
  • Profitability1 of 4
    • ✗Profitable in the newest year-$8 MNet income -$8 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-364.4%-364.4% against Biotechnology's median of -60.5% (243 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-364.4%-364.4% in fiscal 2025 against -1603.6% in 2022.
  • Financial health0 of 1
    • –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Evogene Ltd.'s statements, beside the median of Biotechnology.

Evogene Ltd.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-364.4%-60.5%
Net margin-220.3%-68.9%
Revenue growth, 3 years a year31.8%12.9%
Revenue growth-31.0%15.8%
Free cash flow margin-354.3%-61.5%

1of 7on the Piotroski tests of financial strength

  • Revenue fell 31.0% against the year before.
  • Net loss of $8 million, the 11th loss-making year in a row.
  • Free cash flow was negative: -$14 million.
  • Shareholders' equity is negative: -$0 million.

Evogene Ltd.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Evogene Ltd.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue3.95.6r3.0r1.70.91.00.81.73.46.5
Cost of revenue4.12.4r1.5r0.90.80.60.31.52.85.6
Gross profit−0.23.2r1.5r0.80.20.50.40.30.50.9
Research and development8.013r16r21211716151716
Selling, general and administrative4.37.0r5.4r6.57.35.33.83.53.83.9
Selling and marketing1.52.0r2.2r3.92.72.7————
Total costs and expenses1422r24r28312522202222
Operating income−14−19r−22r−27−31−25−21−20−22−21
Interest and finance income0.40.8r1.0r0.20.30.20.81.42.12.4
Interest expense and finance costs1.93.4r0.9r3.31.43.00.62.21.00.9
Income before tax−13−15r−22r−30−30−26−19−21−21−20
Income tax0.00.00.0r0.10.00.00.00.00.00.0
Income from continuing operations−13−15−22———————
Income from discontinued operations5.7−3.2−4.0———————
Net income including minority interests−7.8−18−26−30−30−26−19−21−21−20
Minority interests' share of net income0.7−1.6−2.1−3.2−2.7−2.8−1.0−0.1——
Net income attributable to shareholders−8.5−16−24−27−28−23−18−21−21−20
Earnings per share, basic1.08-2.90r-5.20r-6.44r-0.69-0.83————
Earnings per share, diluted1.08-2.90r-5.20r-6.44r-0.69-0.83————
Shares, weighted average (basic)7.95.74.6r4.1r402826262625
Shares, weighted average (diluted)7.95.74.6r4.1r4028————
Balance sheet
Cash and cash equivalents131521293246355.83.43.2
Receivables0.31.10.40.30.30.20.10.20.10.2
Inventory0.21.80.10.60.10————
Current assets16223438575249557389
Property, plant and equipment0.81.82.52.52.12.12.63.24.86.5
Right-of-use (leased) assets1.82.41.01.62.11.92.7———
Other intangible assets0121314151617———
Investments in associates0.00.10———————
Non-current assets4.41817181920223.24.86.5
Total assets20405156767271597896
Accounts payable0.61.21.81.01.50.91.01.01.11.3
Current liabilities3.4196.95.66.99.75.7r5.44.75.2
Lease liabilities (non-current)1.51.90.30.91.71.72.1———
Non-current liabilities4.66.315166.05.45.4r3.03.63.5
Total liabilities8.12522———————
Retained earnings−283−274−258−234−207−179−156−138−117−96
Shareholders' equity−0.1−1.51228544650506987
Minority interests1216176.99.811100.3——
Total equity12152935635760506987
Total liabilities and equity20405156767271597896
Shares outstanding8.76.55.1r41413626262625
Cash-flow statement
Depreciation and amortization1.11.4r1.3r1.51.31.82.42.02.12.3
Share-based compensation0.71.2r1.1r1.22.64.11.61.72.22.9
Cash from operating activities−14−20−22−24−25−20−18−15−16−12
Capital expenditure−0.1−0.6−0.6r−1.2−0.8−0.7−0.9−0.4−0.6−0.8
Cash from investing activities189.6−4.513−219.43717154.0
Shares issued————0010———
Cash from financing activities−6.64.7189.330209.30.30.80.7
Exchange-rate effect on cash0.0−0.0−0.2−2.31.11.20.2−0.10.10.0
Change in cash−2.3−5.5−8.2−3.3−1411292.40.2−7.0
Report20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Evogene Ltd. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Business segments

  • Industrial application$2 M56%
  • Agriculture$1 M36%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Acquisitions and funding#

Private share sales · funding history

Private share sales of Evogene Ltd.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2026$3 MPrivate placement after listing$2 to $10 million1optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Evogene Ltd. compares in Biotechnology

  • Market cap$8 M · higher than 9% of 726
  • Revenue$4 M · higher than 34% of 647
  • Net margin-220.3% · higher than 26% of 408
  • Revenue growth-31.0% · higher than 27% of 438
  • Price / sales2.1× · lower than 85% of 339
  • FCF yield-170.5% · higher than 3% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Evogene Ltd.🇮🇱$8 M—-220.3%-31.0%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Aug 1, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Evogene Ltd.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Evogene Ltd.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Evogene Ltd.? Suggest a correction